Bnt162b2 comirnaty

Manufactured by Pfizer

Sourced in United States

BNT162b2/Comirnaty is a messenger RNA (mRNA) vaccine. It is designed to elicit an immune response against the SARS-CoV-2 virus, which causes COVID-19 disease.

Automatically generated - may contain errors

Lab products found in correlation

Mrna 1273 spikevax, by Moderna (2 mentions) Azd1222 vaxzevria, by AstraZeneca (2 mentions) Vaxzevria, by AstraZeneca (1 mentions) Chadox1 s, by AstraZeneca (1 mentions) Bbibp corv, by Sinopharm (1 mentions) Mrna 1273, by Moderna (1 mentions)

5 protocols using bnt162b2 comirnaty

COVID-19 Vaccination and Testing Protocols

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

As part of the Austrian vaccination strategy, more than 8 500 employees of the General Hospital of Vienna in total had been vaccinated twice, either with the COVID-19 mRNA-based vaccine BNT162b2 (COMIRNATY; Pfizer/BioNTech, Inc.) or the COVID-19 viral (chimpanzee adenovirus) vector-based vaccine ChAdOx1-S (VAXZEVRIA, AstraZeneca, Inc.) between January and May 2021 [13] (link). For the entire pandemic period, hospital members of all occupational groups, independent of their vaccination status, were obligated to perform routine testing for SARS-CoV-2 at least once weekly with a nasopharyngeal or nasal COVID-19 Antigen Rapid Test Device (Abbott®), or PCR test according to the test policy of the hospital at that time.

Brunner-Ziegler S., Bäuerle M., Brühl P., Kornek G., Parschalk B., Savic R., Schnetzinger M., Spath T., Straßl R.P., Handisurya A, & Thalhammer F. (2023). Long COVID symptoms in hospital employees after post-vaccination SARS-CoV-2 infection in Austria: A study on self-reported incidence and associated factors. Journal of Infection and Public Health, 16(4), 596-602.

+ Open protocol

+ Expand

Longitudinal SARS-CoV-2 Antibody Dynamics in Milk

Check if the same lab product or an alternative is used in the 5 most similar protocols

This prospective longitudinal cohort study is a follow-up study of the COVID MILK – POWER MILK study.³⁴ (link) All samples were subjected to longitudinal analysis of specific antibodies against SARS-CoV-2 in human milk and serum after vaccination against COVID-19 with either BNT162b2/Comirnaty developed by Pfizer-BioNTech, mRNA-1273/Spikevax developed by Moderna, AZD1222/Vaxzevria developed by Oxford/AstraZeneca and Ad26.COV2.S developed by J&J/Janssen. Ethical approval was acquired from the Independent Ethics Committee of the Vrije Universiteit Medical Center (2020.425/NL74752.029.20). The study was conducted in accordance with the principles of the declaration of Helsinki and the ICH GCP Guidelines, and the Regulation on Medical Research involving Human subjects and reported in adherence to the CONSORT reporting guidelines.

Juncker H.G., Mulleners S.J., Ruhé E.J., Coenen E.R., Bakker S., van Doesburg M., Harinck J.E., Rood R.D., Bouhuijs J.H., Oomen M., de Groot P.C., Pajkrt P.D., Korosi A., van Goudoever P.J., van Gils M.J, & van Keulen B.J. (2022). Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands. eClinicalMedicine, 47, 101393.

+ Open protocol

+ Expand

COVID-19 Vaccination Antibody Response in Breast Milk

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

In this observational longitudinal case series we used samples from an existing prospective longitudinal study COVID MILK – POWER MILK (28 (link)). All participants were subjected to longitudinal analysis of specific antibodies against the SARS-CoV-2 spike-protein by ELISA and general SIgA1 Fab clonal profiling in human milk after vaccination against COVID-19 with BNT162b2/Comirnaty developed by Pfizer-BioNTech, mRNA-1273/Spikevax developed by Moderna or AZD1222/Vaxzevria developed by Oxford/AstraZeneca. Ethical approval was acquired from an Independent Ethics Committee (2020.425/NL74752.029.20). The study was conducted in accordance with the principles of the declaration of Helsinki and the ICH GCP Guidelines, and the Regulation on Medical Research involving Human subjects.

de Graaf S.C., Bondt A., van Rijswijck D.M., Juncker H.G., Mulleners S.J., Damen M.J., Hoek M., van Keulen B.J., van Goudoever J.B., Heck A.J, & Dingess K.A. (2024). A case series exploring the human milk polyclonal IgA1 response to repeated SARS-CoV-2 vaccinations by LC–MS based fab profiling. Frontiers in Nutrition, 10, 1305086.

+ Open protocol

+ Expand

COVID-19 Vaccine Dosing Regimens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Participants under study received both the first and second dose of any one of the following vaccines—BNT162b2/Comirnaty (Pfizer-BioNTech, New York, USA), mRNA-1273 (Moderna, Cambridge, MA, USA), ChAdOx1-S/Covishield (AstraZeneca-Oxford, UK), COVID-19 Vaccine Janssen/Johnson (Janssen Biologics B.V. and Janssen Pharmaceutica NV, Horsham, PA, USA), BBIBP-CorV (Sinopharm, Beijing, China), or Covaxin (Bharat Biotech, Hyderabad, India). The State of Qatar is administrating only Moderna, Pfizer-BioNTech, and AstraZeneca vaccines.

Bansal D., Atia H., Al Badr M., Nour M., Abdulmajeed J., Hasan A., Al-Hajri N., Ahmed L., Ibrahim R., Zamel R., Mohamed A., Pattalaparambil H., Daraan F., Chaudhry A., Oraby S., El-Saleh S., El-Shafie S.S., Al-Farsi A.F., Paul J., Ismail A., Al-Romaihi H.E., Al-Thani M.H., Doi S.A., Zughaier S.M., Cyprian F., Farag E, & Farooqui H.H. (2023). Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar. Vaccines, 11(3), 496.

+ Open protocol

+ Expand

COVID-19 Vaccine Authorization Timelines

Check if the same lab product or an alternative is used in the 5 most similar protocols

BBIBP-CorV of Beijing Institute of Biological Products was authorised for emergency utilisation in adults by the National Ministry of Health in February 2021 (report number 688/2021) after recommendation of the National Administration for Drugs, Food and Technology. On 1 October 2021 the authorisation was extended for the use in children older than 3 years. mRNA-1273 (Spikevax) from Moderna and BNT162b2 (Comirnaty) from Pfizer-BioNTech were authorised for the use in adolescents (12-17 years) from 23 July and 28 May 2021 respectively by the Committee for Medicinal Products for Human Use (CHMP) from European Medicines Agency.

González S., Olszevicki S., Gaiano A., Baino A.N., Regairaz L., Salazar M., Pesci S., Marín L., Martínez V.V., Varela T., Ceriani L., Garcia E., Kreplak N., Navarro A., Estenssoro E, & Marsico F. (2022). Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study. Lancet Regional Health - Americas, 13, 100316.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!